ArticleViruses2021

Transient CRISPR-Cas Treatment Can Prevent Reactivation of HIV-1 Replication in a Latently Infected T-Cell Line.

Ye Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.